Maminata Traore / Coulibaly
| Current Job | Biologist Researcher |
| Personal Statement | I am a Biomedical Researcher and the Director of Research in Biochemistry (Natural Products Chemistry) and Microbiology. I Studied at University of Ouagadougou, Burkina Faso and Danish Faculty of Pharmaceutical Sciences, University of Copenhagen. My research activities are focused on infectious diseases: – preclinical and clinical evaluation of medicines and phytomedicines – Biochemistry (Natural Products Chemistry). I Have achieved around 15 founded projects as investigator or co-investigator and auteur of more than 65 publications and one patent. |
| Education | 2008: PhD in Pharmaceutical Sciences / Chemistry of natural products, University of Copenhagen, Denmark 1996: Doctorate of 3rd cycle in Applied Biological Sciences, Biochemistry and Microbiology, University of Ouagadougou, Burkina Faso 1992: DEA in Applied Biological Sciences, Biochemistry and Microbiology, University of Ouagadougou, Burkina Faso 1990: Masters in Applied Biological Sciences, Animal Biology and Physiology, University of Ouagadougou, Burkina Faso 1989: Bachelor in Applied Biological Sciences, Chemistry-Biology, University of Ouagadougou, Burkina Faso |
| Experiences | Academic Position: – CAMES Director of Research, since 2018 – Teacher at Catholic University (UCAO) in Bobo-Dioulasso, Burkina Faso and at University Nazi Boni – Supervision of PhD, Master, Pharmacy and Medicine theses, around 20. Administrative position: – Deputy ministry of Research and Innovation, MESRSI, Burkina Faso – Scientific Director of the Regional Direction of IRSS, based at the Clinical Research Unit of Nanoro, 2016-2021 – Head of the Department “Studies and Monitoring-Evaluation” 2014-2016 – Head of the Department “Studies and Planning”, 2013-2014 – Member of AVAREF/OMS technical committee, 2016-2020 – Member of the health ethics committee (CERS), 2013-2020 |
| Awards / Honors |
– Knight of the Order of Academic Palms – Prize for the best posters (1st and 2nd prize), WANPRES 2012 in Nigeria |
| Research Grants | Grants obtained: 1. 2020-2023 Portfolio approach to developing the next generation of malaria treatments for Africa Phase II EDCTP 2. 2019-2021 : A Phase Ib/IIb randomised controlled trial of the safety, immunogenicity and efficacy of a candidate malaria vaccine, R21 adjuvanted with Matrix-M (R21/MM), in 5-17 months old children in Nanoro, Burkina Faso Phase II EDCTP 3. 2018-2023: Field efficacy testing of a malaria vaccine targeting all four stages of the parasite’s life-cycle Phase II EDCTP 4. 2019-2024: Safety and Efficacy of a newly registered Artemisin-Based Combination (Pyronaridine-Artesunate – PYRAMAX®) for the treatment of uncomplicated malaria in African pregnant women Phase III EDCTP 5. 2016-2017: Phase IV study to evaluate the effectiveness of the fixed-dose artemisinin-based combination therapy Pyramax ® (Pyronaridine-artesunate) in uncomplicated malaria patients in the Nanoro Health District, Burkina Faso Phase IV INDEPTH / Gates Foundation 6. 2016-2020: Pre-delivery administration of azithromycin to prevent neonatal sepsis and death: a phase III double-blind randomized clinical trial Phase III DFID/MRC, UK 7. 2016-2019: A comparative trial of seasonal vaccination with the malaria vaccine RTS,S/AS01, seasonal malaria chemoprevention and of the two interventions combined Phase III DFID/MRC, UK 8. 2015-2017: Extension to study MALARIA-055 PRI (110021) for evaluation of long-term efficacy, safety and immunogenicity of GSK Biologicals’candidate malaria vaccine (SB257049) in infants and children in Africa Phase III GlaxoSmithKline (GSK) |
 |
PubMed Link |
 |
ORCID Link |  |
Publons Link | Publons Link |  |
ResearchGate Link |
 |
Twitter Link |
Click to rate!
[Total: 0 Average: 0]
